10Elms LLP’s iShares Biotechnology ETF IBB Stock Holding History

10Elms LLP’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$385K	Hold	2,025	–	–	0.16%	75
2026 Q1	$342K	Hold	2,025	–	–	0.22%	68
2025 Q4	$342K	Hold	2,025	–	–	0.31%	60
2025 Q3	$292K	Hold	2,025	–	–	0.26%	67
2025 Q2	$256K	Hold	2,025	–	–	0.24%	66
2025 Q1	$259K	Hold	2,025	–	–	0.26%	62
2024 Q4	$268K	Buy	+2,025	New	+$285K	0.28%	60

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

10Elms LLP's IBB Position: Q2 2026 in Review

10Elms LLP held its iShares Biotechnology ETF (IBB) position steady in Q2 2026 at 2,025 shares worth $385K. The position accounts for 0.16% of the portfolio, ranked #75.

10Elms LLP first reported a position in IBB in Q4 2024 and has held it in 7 quarters since. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

10Elms LLP held 2,025 shares of iShares Biotechnology ETF worth $385K as of Q2 2026.
10Elms LLP left its iShares Biotechnology ETF share count unchanged in Q2 2026.
iShares Biotechnology ETF made up 0.16% of 10Elms LLP's portfolio in Q2 2026, its #75 holding.
10Elms LLP first reported a position in iShares Biotechnology ETF in Q4 2024 and has held it in 7 quarters since.
956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on 10Elms LLP's 13F filing for Q2 2026, filed 14 Aug 2026.